Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used

Clinical Chemistry

Volumn 44, Issue 2, 1998, Pages 209-214

  Genser, Norbert ^a   Lechleitner, Peter ^a   Maier, Josef ^a   Dienstl, Franz ^a   Artner Dworzak, Erika ^a   Puschendorf, Bernd ^a   Mair, Johannes ^a,b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Inst Medizinische Chemie Biochemie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CREATINE KINASE; CREATINE KINASE MB; D DIMER; FIBRIN DERIVATIVE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; MYOGLOBIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; TURBIDIMETRY;

EID: 0031934499     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.2.209     Document Type: Article

References (23)

1. Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988;115:776-80.
2. Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen HR. Arnout J, eds. Thrombosis and haemostasis. Leuven: Leuven University Press, 1987:227-65.
3. Hamsten A, Wiman B, De Faire K, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
4. Almér LO, Öhlin H. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res 1987;47:335-9.
5. Paramo JA, Colucci M, Collen D, Van Der Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985;291:575-6.
6. De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
7. ISIS-2. Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin or both or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988;ii:349-60.
8. White HD, Norris RM, Brown MA, Takayam M, Maslowski A, Bass NM, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850-5.
9. Gray RP, Yudkin JS, Patterson DL. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1993;69:228-32.
10. TIMI. Study Group. The Thrombolysis in Myocardial Infarction trial: phase 1 findings. N Engl J Med 1985;312:932-6.
11. Barbash GI, Hod H, Roth A, Miller HI, Rath S, Zahav Y, et al. Correlation of baseline plasminogen activator inhibitor with patency of the infarct related artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989;64:1231-5.
12. Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991;65:275-9.
13. Munkvad S, Gram J, Jespersen J. Increase of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-I) in plasma after thrombolytic therapy of patients with myocardial infarction. A randomised, placebo-controlled study. Fibrinolysis 1992;6:45-50.
14. Rapold HJ, Grimaudo V, Declerck PJ, Kruithof EKO, Bachmann F. Plasma levels of plasminogen activator inhibitor type-1, β-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with Alteplase. Blood 1991; 78:1490-5.
15. Sakata K, Hoshino T, Yoshida H, Ono N, Ohtani S, Yokoyama S, et al. Circadian fluctuations of tissue plasminogen activator antigen and plasminogen activator inhibitor-1 antigens in vasospastic angina. Am Heart J 1992;124:854-60.
16. Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart ACW, Aber VR, et al. Major Circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988;62:635-7.
17. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-6.
18. Lucore CL, Sobel BE. Interaction of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988;77:660-9.
19. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, et al. Plasma plasminogen activator inhibitor-1 in angina pectoris. Arteriosclerosis 1989;9:362-7.
20. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
21. Lew AS, Berberian L, Cercek B, Lee S, Shah PK, Ganz W. Elevated serum D-dimer: a degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. J Am Coll Cardiol 1986;7:1320-4.
22. Munkvad S, Jespersen J, Gram J, Kluft C. Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium. J Intern Med 1990;228:361-5.
23. Andreotti F, Roncaglioni MC, Hackett DR, Khan MT, Regan T, Haider AW, et al. Early coronary reperfusion thrombolysis blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990;16:1553-7.